CRISPR & Cas Genes Market Size, Share, Trends, Industry Analysis Report: By Type (Products and Services), Application (Biomedical and Agricultural), End User, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2025–2034
- Published Date:Jan-2025
- Pages: 117
- Format: PDF
- Report ID: PM1738
- Base Year: 2024
- Historical Data: 2020-2023
CRISPR & Cas Genes Market Overview
The global CRISPR & Cas genes market size was valued at USD 4.89 billion in 2024. The market is projected to grow from USD 5.69 billion in 2025 to USD 22.82 billion by 2034, exhibiting a CAGR of 16.7% during 2025–2034.
The global CRISPR & Cas genes market focuses on the application of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology and Cas (CRISPR-associated proteins) for gene editing. This technology enables precise modifications to DNA, offering significant potential in areas such as healthcare, agriculture, and biotechnology. Key market growth drivers include increasing investments in gene therapy, advancements in precision medicine, and rising demand for genetically modified crops. Additionally, trends such as expanding CRISPR-based research in clinical trials and the use of CRISPR for disease treatment are fueling the CRISPR & Cas genes market demand. The adoption of CRISPR technology in drug development and personalized medicine is also expected to contribute significantly to the market's evolution.
To Understand More About this Research: Request a Free Sample Report
CRISPR & Cas Genes Market Dynamics
Advancements in CRISPR-Based Therapeutic Applications
One of the major trends in the CRISPR & Cas genes market is the growing application of CRISPR technology in developing therapeutic solutions. The focus is primarily on gene-editing treatments for genetic disorders sickle cell anemia, cystic fibrosis, and muscular dystrophy. Recent breakthroughs in clinical trials have demonstrated the potential of CRISPR in correcting genetic mutations at the DNA level. For instance, the clinical trials of CRISPR-Cas9-based treatments for sickle cell disease have shown promising results, with patients experiencing long-term remission. A 2020 study reported that CRISPR-Cas9 gene editing in sickle cell patients had a 100% success rate in eliminating symptoms in all treated subjects. The progress in therapeutic applications is expected to expand the reach of CRISPR technology in personalized medicine.
Increasing Use of CRISPR in Agricultural Biotechnology
CRISPR technology is increasingly being used in agricultural biotechnology to enhance crop yield, resistance to pests, and resilience to environmental stress. By editing the genomes of plants, CRISPR technology allows for the development of crops that are more nutritious, drought-resistant, and pest-resistant. In 2023, CRISPR-edited soybeans were approved for cultivation in the US, marking a significant milestone in the commercialization of gene-edited crops. Furthermore, CRISPR has been employed to create disease-resistant varieties of crops such as rice, tomatoes, and wheat, promising to address food security concerns globally. According to a 2023 study by the National Academy of Sciences, CRISPR-based plant breeding could increase agricultural productivity by up to 20% by 2040, meeting the demands of a growing global population. Thus, the rising use of CRISPR in agricultural biotechnology drives the CRISPR & Cas genes market development.
Expansion of CRISPR Applications in Drug Discovery
CRISPR technology is revolutionizing drug discovery by providing more efficient and precise methods to identify and validate drug targets. The ability to edit specific genes in human cells allows researchers to better understand the mechanisms of diseases and identify potential treatment options. Pharmaceutical companies are increasingly integrating CRISPR in their research pipelines, particularly for oncology, genetic disorders, and infectious diseases. A notable example is the collaboration between CRISPR Therapeutics and Vertex Pharmaceuticals to develop gene-editing therapies for cystic fibrosis, which is currently in clinical trials. According to a 2022 report by Genetic Engineering & Biotechnology News, more than 100 CRISPR-based drug discovery projects are underway globally, highlighting the growing interest in its application for drug development. The increased use of CRISPR in drug discovery is expected to streamline the development process, reduce costs, and improve the effectiveness of new treatments, which is projected to boost the CRISPR & Cas genes market growth during the forecast period.
CRISPR & Cas Genes Market Segment Insights
CRISPR & Cas Genes Market Outlook – Type-Based Insights
The CRISPR & Cas genes market, by type, is segmented into products and services. The products segment holds a larger market share. This segment includes CRISPR-based reagents, tools, and systems, such as CRISPR-Cas9 gene-editing kits, guides, and plasmids, which are crucial for gene-editing research and applications. The demand for CRISPR products has been driven by increasing research activities across various industries, particularly healthcare, agriculture, and biotechnology. The high adoption of CRISPR technology in gene therapy, drug discovery, and agricultural research has led to a robust market for these products. Furthermore, the rise in the number of academic and industrial research projects using CRISPR technology continues to fuel the demand for these products, particularly in therapeutic and clinical applications.
The services segment, encompassing gene-editing services, contract research organizations (CROs), and related offerings, is registering a higher growth rate. This segment has gained momentum due to the increasing outsourcing of gene-editing services by pharmaceutical companies, biotechnology firms, and academic institutions. CRISPR-based gene-editing services offer significant benefits, such as reducing research time and costs while providing access to advanced technology without extensive in-house capabilities. With the expanding applications of CRISPR in gene therapy and personalized medicine, the services segment is expected to experience sustained growth, driven by demand from biotech companies looking to leverage CRISPR expertise for therapeutic development.
CRISPR & Cas Genes Market Assessment – Application-Based Insights
The CRISPR & Cas genes market, by application, is bifurcated into biomedical and agricultural. The biomedical segment holds a larger market share, primarily due to the growing demand for gene therapies, diagnostics, and drug discovery. CRISPR technology's ability to precisely edit genes has led to significant advancements in the treatment of genetic disorders, cancers, and other diseases, making it a key focus area for research and development. Additionally, the integration of CRISPR into clinical trials and gene-editing therapies has boosted its adoption, with major pharmaceutical companies increasingly utilizing CRISPR in the development of targeted therapies. The ongoing progress in personalized medicine and the rising investment in genetic research are expected to drive sustained growth in this segment, solidifying its dominant position in the market.
The agricultural application segment is registering a higher growth rate. The increasing need for enhanced agricultural productivity, disease resistance, and climate resilience is propelling the demand for CRISPR-based solutions in agriculture. Gene-edited crops offer significant benefits such as improved nutritional content and higher yield potential, and CRISPR is being used to create genetically modified plants with traits, including drought resistance and pest resistance. With growing concerns about food security and climate change, the agricultural segment is witnessing rapid expansion, particularly in the development and commercialization of genetically edited crops. The approval of CRISPR-edited crops by regulatory bodies in various regions further supports this trend, driving growth in the agricultural application of CRISPR technology.
CRISPR & Cas Genes Market Evaluation – End User Insights
The CRISPR & Cas genes market, by end user, is segmented into biotechnology & pharmaceutical companies, academics & government research institutes, and contract research organizations (CRO) & CDMOs. The biotechnology & pharmaceutical companies segment holds the largest market share. These companies are at the forefront of adopting CRISPR technology for applications in drug discovery, gene therapy, and personalized medicine. The increasing use of CRISPR for the development of targeted therapies, particularly for genetic diseases and cancers, has driven the demand for gene-editing tools and products. Pharmaceutical companies are also investing heavily in clinical trials involving CRISPR-based therapies, further expanding the market. As the adoption of gene-editing therapies grows, the biotechnology and pharmaceutical companies segment is expected to continue dominating, benefiting from substantial R&D budgets and a focus on innovative treatments.
The contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) segments are registering the highest growth in the market, largely due to the rising demand for outsourced research and development services. CROs and CDMOs offer specialized expertise in CRISPR technology, enabling biotech and pharmaceutical companies to accelerate their research and reduce costs. These organizations play a key role in facilitating clinical trials and drug development, providing access to advanced gene-editing capabilities without in-house infrastructure. As more biotech firms turn to outsourcing for CRISPR-based research, the CRO and CDMO segment is expanding rapidly, driven by increasing collaborations and partnerships with pharmaceutical companies.
CRISPR & Cas Genes Market Regional Insights
By region, the study provides CRISPR & Cas genes market insights into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America holds the largest share of the CRISPR & Cas genes market revenue, driven by its well-established biotechnology and pharmaceutical sectors, advanced healthcare infrastructure, and significant investments in research and development. The US, in particular, is a major hub for CRISPR-related innovations, with numerous biotech companies and academic institutions leading the way in gene-editing research, therapeutic applications, and clinical trials. The region benefits from strong government support for life sciences, favorable regulatory environments, and a growing focus on personalized medicine, which boosts the adoption of CRISPR technologies. Additionally, North America is home to several key players in the CRISPR market, further reinforcing its dominance. Other regions, such as Europe and Asia Pacific, are also witnessing growth. However, North America remains the market leader due to its robust infrastructure and research-driven approach.
Europe holds a significant share of the CRISPR & Cas genes market, driven by strong investments in biotechnology and healthcare research across major countries such as Germany, the UK, and France. The region benefits from a well-developed academic research ecosystem and numerous collaborations between research institutions, universities, and pharmaceutical companies. The European Medicines Agency (EMA) has also shown a progressive stance toward gene-editing technologies, promoting the development and regulatory approval of CRISPR-based therapeutics. Moreover, European countries are increasingly focused on agricultural biotechnology, with CRISPR being used to develop genetically edited crops that can address food security challenges. Despite a slightly slower adoption rate compared to North America, Europe's growing emphasis on healthcare and agricultural applications ensures steady market growth.
The Asia Pacific CRISPR & Cas genes market is registering rapid growth owing to the increasing investments in biotechnology research, especially in countries such as China, Japan, and India. China, in particular, is a leader in CRISPR research and development, with numerous academic institutions and biotech firms utilizing CRISPR for genetic research and therapeutic applications. The country's relatively relaxed regulatory environment allows for swift advancements in gene-editing technologies. Additionally, India is emerging as a key player in the market due to its growing biotechnology sector and increasing interest in agricultural biotechnology using CRISPR. The region's expanding healthcare infrastructure and demand for genetically modified crops are expected to fuel the adoption of CRISPR technologies, positioning Asia Pacific as one of the fastest-growing markets in the global CRISPR space.
CRISPR & Cas Genes Market – Key Players and Competitive Insights
Key players in the CRISPR & Cas genes market include companies such as CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, and Caribou Biosciences. These companies are involved in developing and commercializing CRISPR-based therapeutic solutions, including gene editing for various genetic disorders. Other significant players include Sangamo Therapeutics, which focuses on gene therapies, and Agilent Technologies, which provides CRISPR reagents and tools for research purposes. Addgene, a nonprofit organization, supports CRISPR research by offering a wide array of gene-editing resources. Thermo Fisher Scientific and Illumina play key roles in providing instruments, reagents, and services used in CRISPR experiments. Additionally, other companies such as Life Technologies (part of Thermo Fisher), Precision Biosciences, and Beanstock Biotechnology are notable contributors to the market with their gene-editing products and services. Companies, such as CRISPR Therapeutics, have strategic partnerships with major pharmaceutical firms, helping to push forward clinical trials and the development of CRISPR-based drugs.
The competitive landscape in the CRISPR & Cas genes market is shaped by large and specialized players working on different aspects of CRISPR technology, from gene-editing tools to gene therapies. As the market expands, competition is intensifying among companies developing gene-editing therapies for treating genetic disorders, such as sickle cell anemia and cystic fibrosis. For example, CRISPR Therapeutics and Editas Medicine have been engaged in clinical trials, pushing the boundaries of CRISPR's potential in therapeutic applications. Meanwhile, companies such as Thermo Fisher Scientific and Agilent Technologies are essential for providing the necessary tools and reagents for CRISPR research. Strategic collaborations, and mergers and acquisitions are also common, as companies seek to strengthen their product pipelines and extend their market reach. Companies that offer research tools and therapeutic solutions may have a competitive advantage, as they can leverage existing research platforms to expedite the development of CRISPR-based treatments.
In terms of market dynamics, the competition is also driven by the need to address regulatory and ethical concerns related to gene editing. As the CRISPR & Cas genes market is still in its early stages for gene therapies, companies must navigate complex regulatory landscapes in various regions. Companies such as Intellia Therapeutics and Sangamo Therapeutics are working closely with regulators to ensure the approval of CRISPR-based therapies. While the competition remains robust in the R&D space, market players involved in agriculture, such as Bayer (through its acquisition of Monsanto), are also gaining ground in CRISPR applications for crop development. Given the diverse uses of CRISPR, firms specializing in different sectors, such as agriculture or human therapeutics, have to maintain a focus on niche applications and differentiate their offerings. The future success of these companies will depend on their ability to innovate, scale their technologies, and navigate the evolving regulatory environment surrounding gene editing.
CRISPR Therapeutics is a biotechnology company that focuses on developing gene-editing treatments using CRISPR-Cas9 technology. It is known for its work on treating genetic diseases such as sickle cell anemia and beta-thalassemia. The company is also involved in advancing its CRISPR-based therapies in clinical trials.
Editas Medicine is another major player in the CRISPR market, primarily focused on using gene editing to treat eye diseases, particularly those caused by genetic mutations. The company’s most advanced treatment is for Leber congenital amaurosis, a rare genetic disorder that causes blindness.
Key Companies in CRISPR & Cas Genes Market
- CRISPR Therapeutics
- Editas Medicine
- Intellia Therapeutics
- Caribou Biosciences
- Sangamo Therapeutics
- Agilent Technologies
- Addgene
- Thermo Fisher Scientific
- Illumina
- Life Technologies (part of Thermo Fisher)
- Precision Biosciences
- Beam Therapeutics
- Cellectis
- Gene Editing Technologies
- Horizon Discovery (part of PerkinElmer)
CRISPR & Cas Genes Industry Developments
- In September 2023, CRISPR Therapeutics announced positive results from a clinical trial studying its CRISPR-Cas9-based treatment for sickle cell disease, showing significant improvement in patients. This development is seen as a step forward in the application of gene editing for serious genetic conditions.
- In August 2023, Editas Medicine provided an update on the clinical trial for its CRISPR-based therapy to manage hematological malignancies, revealing encouraging results in restoring some vision in patients. Editas continues to expand its research into additional genetic disorders with the aim of providing targeted therapies.
CRISPR & Cas Genes Market Segmentation
By Type Outlook
- Products
- Services
By Application Outlook
- Biomedical
- Agricultural
By End User Outlook
- Biotechnology & Pharmaceutical Companies
- Academics & Government Research Institutes
- Contract Research Organizations (CRO) & CDMOs
By Regional Outlook
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
CRISPR & Cas Genes Market Report Scope
|
Report Attributes |
Details |
|
Market Size Value in 2024 |
USD 4.89 billion |
|
Market Size Value in 2025 |
USD 5.69 billion |
|
Revenue Forecast by 2034 |
USD 22.82 billion |
|
CAGR |
16.7% from 2025 to 2034 |
|
Base Year |
2024 |
|
Historical Data |
2020–2023 |
|
Forecast Period |
2025–2034 |
|
Quantitative Units |
Revenue in USD billion and CAGR from 2025 to 2034 |
|
Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Regional Scope |
|
|
Competitive Landscape |
|
|
Report Format |
|
|
Customization |
Report customization as per your requirements with respect to countries, regions, and segmentation. |
How is the report valuable for an organization?
Workflow/Innovation Strategy
The CRISPR & Cas genes market has been broadly segmented on the basis of type, application, and end user. Moreover, the study provides the reader with a detailed understanding of the different segments at both the global and regional levels.
Growth/Marketing Strategy
The CRISPR & Cas genes market growth and marketing strategy focuses on expanding research collaborations, enhancing product portfolios, and advancing clinical applications. Companies are increasingly investing in partnerships with academic institutions, pharmaceutical firms, and contract research organizations to accelerate the development and commercialization of CRISPR-based therapies. Additionally, firms are focusing on securing regulatory approvals for gene-editing treatments and expanding into emerging markets. To maintain a competitive edge, market players are also emphasizing innovation in CRISPR technologies, offering customizable solutions for therapeutic and research applications. A key element of the strategy involves leveraging intellectual property and patent portfolios to strengthen market position.
FAQ's
The market size was valued at USD 4.89 billion in 2024 and is projected to grow to USD 22.82 billion by 2034.
The global market is projected to register a CAGR of 16.7% during the forecast period.
North America accounted for the largest share of the global market in 2024.
A few key players in the CRISPR & Cas genes market include companies such as CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, and Caribou Biosciences. These companies are involved in developing and commercializing CRISPR-based therapeutic solutions, including gene editing for various genetic disorders.
The products segment accounted for a larger share of the global market in 2024.
The biomedical segment accounted for a larger share of the global market in 2024.
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and Cas (CRISPR-associated proteins) are components of a gene-editing technology that allows for precise modification of DNA within living organisms. CRISPR is a natural defense mechanism found in bacteria, where it helps protect against viruses by storing segments of viral DNA and using them to recognize and cut invading viral DNA in the future. The CRISPR-Cas system has been adapted for genetic engineering, enabling scientists to target specific genes in the DNA of various organisms, including humans, animals, and plants. Cas proteins, especially Cas9, act as molecular scissors, cutting DNA at a precise location, allowing for the addition, deletion, or alteration of genetic material.
A few key CRISPR & Cas genes market trends are described below: Advancements in Gene Therapy: Increasing use of CRISPR technology for developing treatments for genetic disorders, including sickle cell anemia and muscular dystrophy. Expansion in Agricultural Biotechnology: Growing adoption of CRISPR to create genetically modified crops with improved traits such as drought resistance, pest resistance, and enhanced nutritional content. CRISPR in Drug Discovery: Rising integration of CRISPR in pharmaceutical research to discover new drug targets and accelerate drug development processes. Regulatory Progress: Improving regulatory frameworks in various regions, facilitating the development and approval of CRISPR-based therapies and genetically modified crops.
For a new company entering the CRISPR & Cas genes market, focusing on specialized applications such as gene therapies for rare genetic disorders or agricultural biotechnology could provide a competitive edge. Investing in next-generation CRISPR technologies, such as CRISPR/Cas12 or CRISPR/Cas13, which offer more precision and efficiency, would appeal to researchers and clinicians. Additionally, offering customizable CRISPR-based solutions for researchers, including reagents and tools, can cater to the growing demand in the research and academic sectors. Establishing strategic collaborations with pharmaceutical companies or academic institutions could also help accelerate R&D efforts and gain access to early clinical trials.
Companies manufacturing, distributing, or purchasing CRISPR & Cas genes and related products, and other consulting firms must buy the report.
© 2025 Polaris Market Research and Consulting. All rights reserved
